Contrast Echocardiography in Non-ST Elevation Myocardial Infarction

Non-ST-Elevation Myocardial Infarction Clinical Trial

Official title:

Contrast Echocardiography in Assessment of Myocardial Perfusion in Patients With Non-ST Elevation Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01122069
• Other study ID #: MCE-NSTEMI
• Secondary ID: REK237.07
• Status: Completed
• Phase: N/A
• First received: May 10, 2010
• Last updated: May 11, 2010
• Start date: March 2008
• Est. completion date: July 2009

Study information

• Verified date: December 2007
• Source: University of Bergen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway: Regional Committee for Medical and Health Research Ethics, Health Region West.
• Study type: Observational

Clinical Trial Summary

In patients with acute myocardial infarction, treatment logistics are primarily defined based upon ST segment shift in the electrocardiogram. While patients with ST elevation (STEMI) are forwarded to immediate coronary angiography and percutaneous coronary intervention, patients without ST elevation (NSTEMI) are initially medically treated and recommended coronary angiography within 48-72 hours.

Early invasive treatment has been found cost-effective in intermediate and high-risk NSTEMI patients and current guidelines recommend use of the Thrombolysis in Myocardial Infarction (TIMI) risk score to identify patients who will benefit from early intervention due to high risk of new infraction and cardiovascular death. However, new research has suggested that TIMI risk score may not always identify patients with severe angiographic disease.

The purpose of this study was to assess if contrast echocardiography could be used to identify NSTEMI patients with angiographically severe disease independent of their TIMI risk score.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• acute non-ST elevation myocardial infarction

Exclusion Criteria:

• hemodynamic unstable

• mechanical prosthetic heart valve

• severly reduced pulmonary function

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Non-ST-Elevation Myocardial Infarction

Intervention

Other:
• Perflutren Lipid Microsphere ultrasound contrast
Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus

Locations

Country	Name	City	State
Norway	Department of Heart Disease, Haukeland University Hospital	Bergen

Sponsors (2)

Lead Sponsor	Collaborator
University of Bergen	Haukeland University Hospital

Country where clinical trial is conducted

Norway,